| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.01 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.01 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.074 | 0.01 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.01 |